Edgewise Therapeutics stock skyrocketed to a three-year high on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients. Please watch the video at Investors.com ...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders ...

Edgewise Networks will significantly improve the security of east-west communication by verifying the identity of application software, services and processes, Zscaler said. Zscaler has purchased ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Hold recommendation. Analyst Price Forecast Suggests 84.07% Upside As of December ...

January 13, 2025--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy. The stock rose 5.4% to $29.11 ...

Investors in Edgewise Therapeutics Inc (Symbol: EWTX) saw new options become available today, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is ...

- Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics (Photo ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...